In light of the considerable therapeutic potential, we propose a Drosophila–based high-throughput screening framework to evaluate herbal drug candidates, focusing on the FOXO-SP as a key regulatory node in T2DM. The gene discussed is TFF2; the disease is type 2 diabetes mellitus.